reported to be significantly correlated with the evolution of RAEB and RAEB-t to overt acute myeloid leukemia. Finally, WT1 has been enclosed in a set of few genes characterizing the transcriptome profile of CD34 þ cells purified from the peripheral blood of patients affected by idiopathic myelofibrosis.
Our results show that bortezomib and vorinostat are able to reduce the expression of one of the most relevant oncogenes involved in hematological malignancies, either when used separately or, interestingly, with a synergistic effect when coadded to our cell lines. These data are in line with those published by other authors that reported that depsipeptide, one of the most effective HDAC inhibitors, exerted a proapoptotic effect on human myeloid leukemic cell lines HL-60 and K562 where mitochondrial translocation of Bax were markedly enhanced by the proteasome inhibitor bortezomib. 8 Interestingly, recently it has been reported that 5-azacytidine, a DNA methyltransferase inhibitor, induces DNA-double-strand breaks, apoptosis and synergistic cytotoxicity with bortezomib against multiple myeloma cells. Considering the well-proven efficacy of 5-azacytidine in MDS, and results coming from our study, a combination of these two drugs in MDS patients would be promising. Nevertheless, in the absence of further data, the combinated use of bortezomib and vorinostat could be considered with caution in patients affected by high-risk MDS because of their antagonistic anti-proliferative effect observed in our P39 model.
In conclusion, if these results will be confirmed by further ex vivo studies, treatment by bortezomib in combination with vorinostat could be an interesting help in treatment of patients affected by acute leukemia or MDS showing high WT1 levels at diagnosis. Transfusion is employed in virtually every adult patient with acute leukemia and leads to immunomodulatory effects that are not yet characterized fully. 1 These effects include downregulation of Th1 immunity and reciprocal activation of Th2 immunity. 2 Thus avoiding, or reversing the effects on cellular immunity due to transfusion in patients with acute leukemia is a potential strategy for improved clinical outcomes. A growing body of data from in vitro animal and clinical studies suggests that blood transfusion has clinically relevant immunologic effects on patients, and that these effects are at least in part due to altered T-cell function. 1 The literature on the effects of transfusion on recipient immunologic function and clinical outcomes is extensive but largely restricted to surgical settings. It is not known whether similar effects occur in patients with hematologic malignancies.
S Galimberti
Infusion of ABO-mismatched platelets is associated with an increased incidence of multi-organ failure and death in stem cell transplants for acute myeloid leukemia. 3 In many centers, the approach to platelet transfusion is to give little or no priority to ABO matching of donors and recipients. One reason is that ABO mismatching of donor and recipient has little effect on clinical outcome in allogeneic stem cell transplantation. 4 We hypothesized that immune function may be important in eradicating residual disease during and after induction therapy in acute leukemia and that transfusion might alter immune function. We examined retrospectively the survival in adult patients with acute leukemia who systematically participated in different protocols for transfusion including ABO identical versus nonidentical platelets, leukoreduced versus non-leukoreduced transfusions and washed versus unwashed transfusions.
To review the association of blood transfusion practice and clinical outcomes in acute leukemia, we chose the period 1985-1994 as these years spanned a period including two randomized transfusion trials in patients with acute leukemia in our hospital, and detailed clinical information had already been collected. The medical records of 120 consecutive patients were analyzed, of whom 115 had complete records available for review. Each patient received treatment with curative intention, that is, fulldose myeloablative chemotherapy was initiated shortly after diagnosis. Most of these patients (n ¼ 83) were participants in two separate randomized trials of ABO identical versus ABO-unmatched platelet transfusions, 5 and a trial of washed, leukoreduced ABO identical versus unwashed, leukoreduced, ABO identical transfusions. 6 Virtually all (495%) platelet transfusions were whole blood-derived random platelets prepared by the platelet-rich plasma method, which were pooled just prior to transfusion. Apheresis platelets were employed solely for refractory patients receiving human leukocyte antigenmatched transfusions. Leukoreduction, if performed, occurred immediately prior to transfusion. While many supportive care practices and post-remission therapies have changed since the time these patients were treated, a disadvantage, induction therapy is relatively unchanged. Full details of the methods employed are available online (http://www.nature.com/leu).
The initial clinical and demographic characteristics of these patients are shown in Table 1 , according to total amount of platelets transfused during their admission for remission induction. Similar results were found for other groupings of platelet dose, including dividing the patients into equal tertiles or quartiles (data not shown).
Treatment and clinical outcome variables are shown in Table 2 . The patients receiving higher doses of platelets required more transfusions at least in part because they required more cycles of chemotherapy to achieve remission, had more bleeding and longer admissions. However, those receiving the most transfusions were also most likely to receive ABOunmatched, non-leukoreduced, unwashed transfusions.
Survival according to dose of platelets transfused during the initial induction therapy admission is shown in Figure 1 .
Recipients of lower numbers of platelet transfusions had strikingly better survival than those receiving greater number of transfusions, with four patients alive at greater than 10 years post-treatment and nine at greater than 5 years. This survival advantage was also observed in patients entering complete remission with a single course of chemotherapy (n ¼ 54; P ¼ 0.015) and those without bleeding (data not shown). This association of longer survival with lower doses of platelets remained significant in two or more variable Cox proportional hazards regressions (Po0.05) after adjusting for covariates such as patient age, presenting white cell or blast count, gender, presence of unknown, favorable, unfavorable or standard risk cytogenetics, type of post-remission therapy (for example, stem cell transplantation versus no transplantation) or phenotype of 
test (categorical variables).
Letters to the Editor leukemia. Similar data on the dose of red cells is shown in Figure 2 . Dose of red cells, unlike platelet transfusion dose, had no discernable association with survival. While patients receiving 4175 platelets also received many more red cells, higher red cell usage was not by itself associated with poorer survival. Employing alternative cutoff levels of red cell transfusion number (for example, o15 versus X15) yielded identical results, confirming the lack of association between number of red cells transfused and survival. As patients receiving ABO identical, leukoreduced, washed transfusions tended to receive fewer transfusions to maintain their platelet counts above the 20 000 ml À1 threshold used during the study period, we also analyzed survival according to the platelet-transfusion protocol used for each patient (Tables 3   and 4 ; Figure 3) . Patients who received washed transfusions had significantly better survival than each of the other groups, despite having a greater proportion of patients with unfavorable risk cytogenetics, but perhaps in part because they were significantly younger than the other cohorts.
In Cox proportional hazard regression analyses, platelet dose remained the only additional significant independent predictor of survival (P ¼ 0.039) other than patient age (Po0.0001). When patients o50 years of age were analyzed, only receipt of washed, leukoreduced, ABO identical platelet transfusions was a significant predictor of survival in Cox regressions (P ¼ 0.014) (P-value for age ¼ 0.56). In these younger patients, age and platelet dose, as well as cytogenetics were no longer independent predictors of survival as compared Survival is shown in a Kaplan-Meier plot as a function of number of red cell units transfused during admission for initial remission-induction therapy. Symbols represent patients still alive at last-recorded follow-up (censored observations). There was no difference in survival associated with differing doses of red cell transfusions (P ¼ 0.74 by the log-rank test). 
Letters to the Editor with receipt of washed transfusions. In addition, there was a trend to lower mortality during the initial admission in patients receiving washed transfusions (approximately half that of the other cohorts) although this difference did not achieve statistical significance (P ¼ 0.13 for washed versus non-washed as a dichotomous variable). Similarly, there was a non-significant trend toward reduced bleeding and reduced numbers of positive bacterial cultures as transfusions became more closely matched and white cells and supernatant plasma were removed by filtration and washing respectively. As expected, as transfusions became more immunologically matched and non-immunogenic (ABO identical and leukoreduced), the need for transfusions of platelets, and human leukocyte antigen-matched platelets both decreased significantly and dramatically. The need for red cell transfusions did not change. In summary, 120 consecutive adult patients with acute leukemia treated during 1985-1994 were analyzed to determine if dose or kind of platelet transfusions (ABO identical versus ABO unmatched, leukoreduced versus non-leukoreduced, washed versus not washed) was associated with overall survival. Increased doses of platelet transfusion during induction therapy were associated with decreased survival. Patients receiving p100 units of platelets (n ¼ 63) had a 24% survival at 5 years, compared with 14% in those receiving 101-175 units (n ¼ 36) and 0% in those receiving 4175 units (n ¼ 16) (P ¼ 0.0099). This survival advantage was also observed in patients entering complete remission with a single course of chemotherapy (n ¼ 54; P ¼ 0.015), and after adjustment for age or cytogenetics. No such effect was seen for red cell transfusion dose, suggesting that this association is specific to platelet transfusions. Survival was also significantly longer in patients receiving ABO identical, leukoreduced, washed transfusions. These observations suggest the hypothesis that transfusion of larger doses of stored platelet supernatant, ABO-mismatched antigen and antibody and allogeneic white cells may unfavorably affect survival in acute leukemia. Platelet transfusions are predominately given as prophylaxis and current guidelines suggest 10 000 ml À1 as a safe threshold, thus current patients may receive considerably fewer platelet transfusions on average than patients reported in our study. Prospective studies will be required to determine whether washed, leukoreduced, ABO identical platelet transfusions or reduced platelet transfusion doses lead to improved survival in acute leukemia.
In addition to a possible survival benefit, patients receiving washed, leukoreduced ABO identical transfusions required fewer platelet transfusions, despite a 20-30% loss of platelets during the leukoreduction/washing process. This suggests that there may be reduced consumption of platelets in patients transfused according to this washed protocol. Speculatively, this might be due to reduced formation of antiplasma protein Chronic lymphocytic leukemia (CLL) is a heterogeneous disease characterized by the accumulation of mature B cells incapable of undergoing apoptosis. Constitutively activated signaling proteins, such as phosphatidylinositol 3 (PI3)-kinase and Protein kinases C (PKCs), contribute to the defect of the programmed cell death. It has also become increasingly evident that a distinct compartment of proliferative cells account for the progression of the disease. Such dividing B-CLL cells can be found in the so-called proliferation centers in the spleen and bone marrow of CLL patients, although the underlying signals that drive cells into the cell cycle are not well defined. While disease progression is dependent on proliferative B-CLL cells rather than on G1-arrested cells, therapies aimed at blocking cell cycle progression seem to be a new and striking approach to the treatment of CLL patients.
Leflunomide (SU101 or HWA 486) is a novel isoaxzole derivate that in vivo becomes rapidly converted to its active metabolite A77 1726. Because the drug has an antiproliferative effect on human T cells, it was introduced in the treatment of rheumatoid arthritis and other autoimmune diseases. Leflunomide specifically inhibits the activity of dihydro-orotate dehydrogenase (DHODH) in a non-competitive manner. 1 DHODH is the rate-limiting enzyme in the de novo biosynthesis of pyrimidines. While its antiproliferative effect on lymphocytes and mononuclear cells is completely reversible by exogenous uridine, blockade of DHODH is considered to be the main mode of action. However, other targets have been defined and may contribute to the inhibitory effects of Leflunomide regardless of the availability of pyrimidines: Leflunomide inhibits platelet-derived growth factor receptor-mediated signal transduction including tyrosine phosphorylation and cell cycle progression. Importantly, doses required to block tyrosine phosphorylation are approximately 10-to 100-fold higher than those needed to block pyrimidine synthesis. 2 However, some reports have pointed to other potential effects of Leflunomide, including downregulation of cytokine production and decreased expression of cytokine receptors.
Because activated lymphocytes have a high demand for pyrimidines during proliferation, we hypothesized that Leflunomide potentially could block cell cycle progression of malignant B-CLL cells and therefore be a potential new drug in the treatment of the disease.
Stimulation of CLL cells with CpG oligonucleotides, such as DSP30, and interleukin-2 (IL-2) can rapidly and robustly induce cell proliferation in B-CLL cells in the absence of 'contaminating T cells'. DSP30 is a single stranded, phosphorothioate stabilized oligonucleotide (n ¼ 27) which carries an unmethylated CpG motif. Using such an in vitro model for B-CLL cell proliferation, we tested whether Leflunomide (or its active metabolite Teriflunomide) can block cell growth of purified malignant B cells. DSP30/IL-2-stimulated B-CLL cells were cultured in the presence of increasing doses of Teriflunomide (range 0.5-100 mM) and cell viability was determined by an MTT assay after 72 h of culturing cells. (Cells were purified and cultured as described previously.) 3, 4 We observed that Teriflunomide induced a decrease of viable cells in a dose-dependent manner. Importantly, a dose of 10 mM Teriflunomide was sufficient to decrease cell proliferation compared to DSP30/IL-2-stimulated cells in the absence of the inhibitor (P ¼ 1.36 Â 10 À7 , Figure 1a ). Such doses are below those needed to achieve similar effects on peripheral blood mononuclear cells of normal donors, indicating that CLL cells are very sensitive to Teriflunomide (data not shown). However, at high concentrations, the cell inhibitory effects were similar to those achieved by rapamycin treatment.
